Tacrine (Cognex®), the first-generation acetylcholinesterase (AChE) inhibitor approved by the U. S. Food and Administration (FDA) for the treatment of Alzheimer’s disease (AD) in 1993 [2,3], has already been tested on a variety of cancer cell lines, to assess its potential for repurposing to oncological pharmacotherapy [4,5,6,7,8]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.